Additionally, RELB scores were associated with lower tumor mutational burden, poorer response to immunotherapy, different drug sensitivity patterns, and increased expression of several antibody-drug conjugate targets.<h4>Conclusion</h4>The study highlights a pro-metastatic ELANE + neutrophil subpopulation, with RELB acting as its primary transcriptional regulator. The gene discussed is ELANE; the disease is neoplasm.